The Gestational Diabetes Market is projected to reach USD 16,040 Million by 2030 at 7.10% CAGR during the forecast period 2022-2030. Diabetes is a metabolic disorder in which the body glucose level is elevated. Gestational diabetes is a temporary or permanent form of diabetes in which the body daoes not produce adequate amounts of insulin to regulate sugar during pregnancy. It may also be called glucose intolerance or carbohydrate intolerance. According to the International Diabetes Federation in 2016, it was estimated that 420 million adult population is suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040. According to the American Pregnancy Association, approximately 2-5% of pregnant women develop gestational diabetes; this number may increase to 7-9% of mothers who are more likely to have risk factors. Increasing prevalence of the gestational diabetic population is the major driving factor for the growth of the gestational diabetes market. Moreover, increasing obese population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the gestational diabetes market. According to research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the gestational diabetes market. However, lack of awareness among people and cost issues may lead to restrain the growth of the market.
Annual reports, Press release, White paper, Company Presentation
The gestational diabetes market is segmented on the basis of types, administration, treatment, and end users.
On the basis of types, the gestational diabetes market is segmented into type A1, type A2 and others.
On the basis of administration, the gestational diabetes market is categorised into oral, intravenous, and other.
On the basis of treatment, the gestational diabetes market is segmented into monitoring, drug treatment, and non-pharmacological treatment. Monitoring is further segmented into urinary glucose testing, oral glucose tolerance test, and others. Drug treatment is subsegmented into insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, and others
On the basis of end users, the gestational diabetes market is segmented into hospital, retail pharmacy and other.
America dominates the gestational diabetes market owing to large patient population. Apart from this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US were diagnosed with high cholesterol level. Increasing cholesterol level and smoking increases the possibility of causing diabetes. Additionally, increasing awareness among the people regarding different monitoring procedures and well-developed technology has also contributed to the growth of the market.
Europe is the second largest gestational diabetes market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market.
Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and increasing need for the better treatment.
On the other hand, the Middle East & Africa has the least share in the gestational diabetes market due to presence of poor economy especially in Africa region. Majority of the market of this region is hold by Middle East due to well-developed healthcare sector and huge healthcare expenditure.
Sources: WHO, annual reports, press release, white paper, and company presentation
Key players for gestational diabetes market
Antares Pharma (US), INJEX Pharma AG (Germany), 3M (US), Eli Lilly (US), Biocon (US), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Novartis (Switzerland), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Merck & Co. (US), Pfizer (US), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), and Takeda (Japan).
|Market Size||USD 16,040 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Types, Administration, Treatment, and End Users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Antares Pharma (US), INJEX Pharma AG (Germany), 3M (US), Eli Lilly (US), Biocon (US), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Novartis (Switzerland), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Merck & Co. (US), Pfizer (US), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), and Takeda (Japan).|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||